<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986426</url>
  </required_header>
  <id_info>
    <org_study_id>C12-315-03</org_study_id>
    <nct_id>NCT01986426</nct_id>
  </id_info>
  <brief_title>LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab</brief_title>
  <official_title>A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lytix Biopharma AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lytix Biopharma AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral&#xD;
      dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune&#xD;
      responses, as monotherapy or in combination with ipilimumab or pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in&#xD;
      patients with transdermally accessible tumours; the safety, PK and efficacy of different&#xD;
      dosing regimens of LTX-315 will be assessed.&#xD;
&#xD;
      Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and&#xD;
      the number of lesions available.&#xD;
&#xD;
      Arm A: Single lesion/sequential lesion treatment arm (LTX-315 monotherapy) (Completed) Arm B:&#xD;
      Concurrent multiple lesion treatment arm with all tumour types (LTX-315 monotherapy) Arm C:&#xD;
      LTX-315 combination with ipilimumab in patients with melanoma Arm D: LTX-315 combination with&#xD;
      pembrolizumab in patients with TNBC&#xD;
&#xD;
      All patients will have at least one lesion available for injection.&#xD;
&#xD;
      Treatment schedule:&#xD;
&#xD;
      Arm A: Injection of LTX-315 3 days week 1, 1 day in week 2, 3, 4, 5 and 6. Every 2 weeks&#xD;
      starting with week 8.&#xD;
&#xD;
      Arm B (all tumours): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16).&#xD;
&#xD;
      Arm C (melanoma): Injection of lTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in&#xD;
      combination with ipilimumab given in week 1 and every 3 weeks 4 cycles.&#xD;
&#xD;
      Arm D (TNBC): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in&#xD;
      combination with pembrolizumab given in week 1 and every 3 weeks up to 2 years.&#xD;
&#xD;
      Patients will be enrolled into a dose cohort in order of study entry. Staring with the lowest&#xD;
      dose. A minimum of 3 patients will be enrolled into each cohort. Dose escalation determined&#xD;
      by the Safety Review Committee and the Sponsor. The the optimal regimen will be based on the&#xD;
      results of the Dose Escalation from the following information:&#xD;
&#xD;
        1. Safety parameters including blood samples and cardiovascular effects&#xD;
&#xD;
        2. Immunohistology and ultrasound confirmation of necrosis and tumour infiltrating&#xD;
           lymphocytes&#xD;
&#xD;
        3. Systemic inflammatory response&#xD;
&#xD;
        4. Evidence of clinical responses&#xD;
&#xD;
      Cohorts may be utilized to:&#xD;
&#xD;
        1. Evaluate different doses of LTX-315&#xD;
&#xD;
        2. Explore potential modifications to the dosing schedule&#xD;
&#xD;
        3. Evaluate the potential to include appropriate combination therapies with LTX-315&#xD;
&#xD;
        4. Gain further information on clinical efficacy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>21 days</time_frame>
    <description>Dose limiting toxicities (DLT) and the overall safety profile (adverse events (AE), laboratory assessments, physical findings and symptomatic assessment) of LTX-315 as monotherapy and in combination with ipilimumab or pembrolizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti tumour activity in injected tumour</measure>
    <time_frame>Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed</time_frame>
    <description>Number of patients with regression of injected tumour assessed by ultrasound and/or CT/MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (irCR) and partial response (irPR)</measure>
    <time_frame>Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed</time_frame>
    <description>Number of patients by irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (OR)</measure>
    <time_frame>Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed</time_frame>
    <description>(irRC criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR + PR + SD)</measure>
    <time_frame>Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed</time_frame>
    <description>irRC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed</time_frame>
    <description>irRC criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic (PK) profile of LTX-315</measure>
    <time_frame>Pre and 1 hour post dosing Day 2 Week 1</time_frame>
    <description>Measurement of plasma concentrations of LTX-315 pre- and 1 hour post-dosing day 2 in week 1.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: LTX-315 monotherapy singe lesion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.&#xD;
Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.&#xD;
Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: LTX-315 monotherapy in multiple concurrent lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:&#xD;
Once daily on 2 consecutive days week 1-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTX-315 consecutive lesions</intervention_name>
    <description>Dose escalation:&#xD;
Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)</description>
    <arm_group_label>Arm A: LTX-315 monotherapy singe lesion</arm_group_label>
    <other_name>Protocol version 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTX-315</intervention_name>
    <description>Dose escalation:&#xD;
Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection</description>
    <arm_group_label>Arm B: LTX-315 monotherapy in multiple concurrent lesions</arm_group_label>
    <other_name>Arm B (Protocol version 6)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTX-315 + ipilimumab</intervention_name>
    <description>Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Arm C (Protocol version 6)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTX-315 + pembrolizumab</intervention_name>
    <description>Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab</description>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Arm D (Protocol version 6)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm A: (Recruitment completed)&#xD;
&#xD;
        Arm B:&#xD;
&#xD;
          -  Unresectable metastatic disease (any tumor type) and conventional anti-tumor treatment&#xD;
             is not appropriate.&#xD;
&#xD;
          -  Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for&#xD;
             injection between 1-3 cm longest diameter and one bystander lesion (non-injected).&#xD;
&#xD;
        Arm C:&#xD;
&#xD;
          -  Have unresectable/metastatic diagnosis of malignant melanoma (histologically&#xD;
             confirmed).&#xD;
&#xD;
          -  Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for&#xD;
             injection and biopsy which is between 1 and 3 cm in longest diameter.&#xD;
&#xD;
          -  Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of&#xD;
             combination (any combination) as 1st or 2nd line metastatic treatment).&#xD;
&#xD;
        Arm D:&#xD;
&#xD;
          -  Have unresectable/metastatic diagnosis of triple negative breast cancer&#xD;
             (histologically confirmed).&#xD;
&#xD;
          -  Have at least one available lesion (cutaneous, sub-cutaneous or lymph node) for&#xD;
             injection and biopsy with a minimum longest diameter of 1 cm.&#xD;
&#xD;
          -  Have received between one and 4 prior systemic treatments for metastatic triple&#xD;
             negative breast cancer.&#xD;
&#xD;
        All arms:&#xD;
&#xD;
          -  Be willing to undergo repeat tumour biopsy and/or tumour resection procedures.&#xD;
&#xD;
          -  Have an ECOG Performance status (PS): 0 - 1.&#xD;
&#xD;
          -  Meet the following laboratory requirements:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               2. Absolute lymphocyte count ≥ 0.8 x 109/L&#xD;
&#xD;
               3. Platelet count ≥ 75 x 109/L&#xD;
&#xD;
               4. Haemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               5. aPTT/PT within the institution's normal range&#xD;
&#xD;
               6. Total bilirubin level ≤ 1.5 x ULN&#xD;
&#xD;
               7. ASAT and ALAT ≤ 2.5 x ULN (≤5 x ULN if liver metastasis present)&#xD;
&#xD;
               8. Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               9. Albumin ≥ 30 g/L&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
                  Arm A: (Completed)&#xD;
&#xD;
                  Arm B:&#xD;
&#xD;
          -  Have a history of systemic auto-immune disease requiring anti-inflammatory or&#xD;
             immunosuppressive therapy within the last 3 months. Patients with history of&#xD;
             autoimmune thyroiditis are eligible provided the patient requires only thyroid hormone&#xD;
             replacement therapy and disease has been stable for ≥ 1 year.&#xD;
&#xD;
        Arm C:&#xD;
&#xD;
          -  Have had prior therapy with ipilimumab or any other anti-CTLA-4 monoclonal antibody.&#xD;
&#xD;
          -  Have had BRAF/MEK inhibitors administered within 2 weeks prior to the study drug&#xD;
             administration.&#xD;
&#xD;
          -  Have active systemic autoimmune disease; have had prior pneumonitis; have a history of&#xD;
             severe hypersensitivity to another monoclonal antibody; are receiving&#xD;
             immunosuppressive therapy; have a history of severe immune-related adverse reaction&#xD;
             from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity&#xD;
             requiring corticosteroid treatment (&gt; 10 mg/day prednisone or equivalent) for greater&#xD;
             than 12 weeks.&#xD;
&#xD;
        Arm D:&#xD;
&#xD;
          -  Have had prior therapy with an anti-PD-1 or anti-PD-L1 monoclonal antibody.&#xD;
&#xD;
          -  Have received cancer immunotherapy within 2 weeks prior to study drug administration&#xD;
             or have not recovered from adverse events (to ≤ CTCAE grade 1) due to such agents.&#xD;
&#xD;
          -  Have active systemic autoimmune disease; have had prior pneumonitis; have a history of&#xD;
             severe hypersensitivity to another monoclonal antibody; are receiving&#xD;
             immunosuppressive therapy; and have a history of severe immune-related adverse&#xD;
             reactions from treatment with a monoclonal antibody, defined as any Grade 4 or 3&#xD;
             toxicity requiring corticosteroid treatment (&gt; 10 mg/day prednisone or equivalent) for&#xD;
             greater than 12 weeks.&#xD;
&#xD;
        All arms:&#xD;
&#xD;
          -  Have received external radiotherapy or cytotoxic chemotherapy within 4 weeks prior to&#xD;
             study drug administration, or have not recovered from adverse events (≤ CTCAE grade 1)&#xD;
             due to agents administered more than 4 weeks earlier. Palliative radiotherapy to&#xD;
             non-target lesions within 4 weeks prior to study drug administration is allowed.&#xD;
&#xD;
          -  Are currently taking any agent with a known effect on the immune system. Patients are&#xD;
             allowed to be on a stable dose of corticosteroids (up to 10 mg daily prednisolone or&#xD;
             equivalent) for at least 2 weeks prior to study drug administration (please see&#xD;
             Appendix IV for prohibited medications).&#xD;
&#xD;
          -  Have any other serious illness or medical condition such as, but not limited to:&#xD;
&#xD;
               1. Uncontrolled infection or infection requiring antibiotics&#xD;
&#xD;
               2. Uncontrolled cardiac failure: Classification III or IV (New York Heart&#xD;
                  Association)&#xD;
&#xD;
               3. Uncontrolled systemic and gastro-intestinal inflammatory conditions&#xD;
&#xD;
               4. Bone marrow dysplasia&#xD;
&#xD;
          -  Have a known history of positive tests for HIV/AIDS, or have active hepatitis B or C&#xD;
             (based on serology).&#xD;
&#xD;
          -  Are expected to need any other anti-cancer therapy or immunotherapy to be initiated&#xD;
             during the study period.&#xD;
&#xD;
             15. Have clinically active or unstable CNS metastases as assessed by the treating&#xD;
             physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Spicer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc, Service d'oncologie médicale</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intotuto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico Venneto (IOV)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London Hospital</name>
      <address>
        <city>London</city>
        <zip>WC 1E</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundatin Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transdermal accessible tumours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

